This study examines whether the level of functioning in hypomania of BD II was more often increased than decreased. In a private practice, 140 consecutively presenting BD II outpatients were interviewed during remission with the Structured Clinical Interview for DSM-IV-Clinician Version (SCID-CV) (2) , as modified by Benazzi and Akiskal (3) . Remission was defined as a Global Assessment of Functioning (GAF) scale score of 80 to 90 for at least 1 month (1). In Italy, private practice is first or second (after family doctors) in the line of treatment of mood disorders. Private practice is more representative of the BD II population than national mental health and university services, where most severe disorders are usually seen. Patients with substance-related and borderline personality disorders (BPDs) were excluded to avoid confounding the diagnosis of BD II (4) and because they are very rarely seen in the private practice setting (5) . Details about study methods are in previous reports (3, 6) . Interviewing during remission should have reduced the negative cognitive bias of depression (7) , which can lead to underreporting positive events. The SCID-CV question on functioning was supplemented by Angst and colleagues' detailed questions about increased functioning during hypomania (8) . Increased functioning was defined according to the DSM-IV text description: there had to be an observable change in functioning (that is, "superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many positive qualities" [1] ). The GAF score had to be 100. The level of functioning most common during an individual's hypomanic episodes was used to rate the subject's functioning as increased, mildly decreased, or never showing marked impairment.
Results
The patients' mean (SD) age was 41.8 (11.7) years; 69.3% (n = 97) were women, and 30.7% (n = 43) were men. More than 1 hypomanic episode was present in 84.3% (n = 118). Increased functioning during hypomania was found in 73.6% (n = 103), and mildly decreased functioning was found in 26.4% (n = 37). These findings suggest that almost 3 out of 4 subjects with BD II, seen in private practice, may have increased functioning during hypomania. Results are in line with classic descriptions of hypomania (9, 10) , which report that most hypomanic episodes show improved functioning. Kraepelin's description of hypomania, based on hospital patients (11) , postulates that some impairment is more likely. Hecker, who worked in private practice, usually found increased functioning (10). Dunner and colleagues' first definition of BD II required no hospital treatment for hypomania and no marked impairment (12) . Later, Dunner and Tay required no impairment (13) , suggesting that hypomania usually has improved functioning.
A limitation of this study is the exclusion of subjects with substance-related disorders and BPD. This subgroup of BD II would be called "dark" by Akiskal and colleagues (14) , because the associated cyclothymic temperament usually causes impaired functioning. The present study's BD II is called "sunny" (14) , because features of cyclothymic temperament (which have similarities with BPD and substance-related disorders) are lacking. Patients with "dark" BD II are more common in tertiary care settings, where the most severely ill patients are seen (40% "dark") (14) . In our setting, most patients with BD II were "sunny" (that is, they had increased functioning during hypomania). By focusing on increased functioning during hypomania, false negatives should be reduced (that is, sensitivity should be higher) and the high BD II underdiagnosis (15) should also be reducedat least in nontertiary care settings. Because subjects with BD II were interviewed during remission, a bias leading to an overestimation of positive aspects of hypomania and an underestimation of possible negative aspects (a common bias during hypomanic episodes) should be significantly reduced. 
Dear Editor
Premenstrual syndrome (PMS) may represent a continuum in a woman's reproductive life, but the mood and physical changes differ in presentation and severity from menarche to menopause (1, 2) . Daily self-rating forms that record symptom pattern and severity are commonly used to confirm the diagnosis of PMS or premenstrual dysphoric disorder (PMDD) (3). Many studies have investigated the severity and chronological relation of symptoms to the menstrual cycle (4,5), but few studies have systematically looked at the impact of premenstrual symptoms in women as they approach perimenopause (2, (6) (7) (8) .
Although there is a definite overlap, it is expected that physical symptoms may be more dominant in women who are later in their reproductive years (8) . Thus, we conducted a pilot study, using self-rating scales to compare the severity of presenting symptoms and levels of distress in women with PMDD under age 40 years (n = 12) vs women age 40 years and over (n = 12). We used 3 questionnaires applied to premenstrual complaints: the Symptom Questionnaire (SQ) (9), the Sheehan Disability scale (SDS) (10) , and the Self-Assessment of Symptoms Questionnaire (SAS). The SQ and SDS are validated scales. We based the SAS on mood and physical symptoms commonly reported during the menopausal transition.
Subjects diagnosed with PMDD gave written informed consent. They completed the questionnaires during the luteal phase (once only), and they reported menstrual history and general demographic data. We conducted independent t-tests to determine the effect of age on distress levels, as measured by the questionnaires.
Our preliminary findings indicate that there are no significant differences between the 2 groups in the mean total scores of distress levels and functional impairment. However, independent t-tests demonstrated a significant between-group difference (P < 0.05) on certain individual items: the group aged under 40 years reported more impairment in social life and leisure activities and more feelings of irritability. The group aged 40 years and over reported more frequent waking at night as well as more early waking. Nevertheless, these results should be viewed with caution because there were few participants, the questionnaires were only completed once, and the measures were not designed specifically for PMDD. The study also did not control for the use of selective serotonin reuptake inhibitors (SSRIs). Seven of the subjects over age 40 years reported current use of SSRIs for PMS, which may have influenced the ratings of mood symptoms. However, taking this into account, our results still indicate that the highest mean score in both groups was irritability, which supports the view that irritability is one of the dominant factors of PMDD (11, 12) .
Our preliminary findings suggest that specific mood and physical symptoms may change throughout the reproductive years, rather than as a whole across the overall clinical picture. Once the diagnosis of PMDD is made, emphasis on certain symptoms throughout the different phases of a woman's reproductive transition may assist in treatment recommendations.
We encourage a larger controlled study using standardized questionnaires to capture the premenstrual symptom profiles at various stages of the reproductive cycle. 
Norwalk Precipitates Severe Lithium Toxicity
Dear Editor:
Despite 50 years of medical experience with lithium, lithium toxicity remains a significant and primarily iatrogenic health problem (1) . The efficacy of lithium is marred by a narrow therapeutic index and significant potential toxicity (2) . Lithium toxicity can occur by overdose (intentional or accidental) or, more commonly, from alteration in its clearance by the kidneys. We present a case of lithium toxicity in an elderly patient subsequent to a "Norwalk virus-like" infection, wherein delay in making the correct diagnosis led to unnecessary suffering and prolonged hospitalization.
Case Report
The patient is a 75-year-old woman with a long history of bipolar illness and
